BofA/Merrill Lynch Starts IMS Health Holdings (IMS) at Buy

BofA/Merrill Lynch initiates coverage on IMS Health Holdings (NYSE: IMS) with a Buy rating and a price target of $28.00.

Analyst Robert Willoughby notes a 99% customer retention rate. Also new management positioned the company for more rapid growth in larger markets with the expansion into analytics and other services that leverage its core data assets, a significantly improved cost structure and a stronger balance sheet. The analyst sees ROIC to improve ahead of the historical rate, which demands a premium valuation.

For an analyst ratings summary and ratings history on IMS Health Holdings click here. For more ratings news on IMS Health Holdings click here.

Shares of IMS Health Holdings closed at $25.21 yesterday.

You May Also Be Interested In

• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• BofA sees dollar weakness continuing with New Zealand dollar gains
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker